SUMMARY: The first injection for Moderna’s vaccine trail in partnership with the National Institutes of Health aims to enroll about 30,000 people from 89 widely dispersed sites across the U.S. It is the first possible coronavirus vaccine to enter a phase three trial in the U.S.  If the vaccine remains on track, Moderna previously said it will be able to deliver “approximately 500 million doses per year, and possibly up to 1 billion doses per year” starting in 2021.The company announced earlier this month that healthy adults whowere given the vaccine in the phase one trial tolerated it generally well and all…

SUMMARY: BioNTech expects to begin phase three trials, at the end of July. Gilead Sciences also announced that test results on remdesivir, the only approved treatment for COVID-19, shows a reduction in mortality in 62 percent of extremely sick patients. Optimism from a potential vaccine and the success of remdesivir also resulted in spike in the US stock market.   Abridged. The CEO of the German company BioNTech told The Hill that he expects the coronavirus vaccine the company is developing in partnership with Pfizer to be ready for approval by December. BioNTech CEO Ugur Sahin said several hundred million doses could be produced even before approval and up to 1.2…